The Effect of Fermented Soy Beverage on Localized Prostate Cancer Patients
Background
Fermented soy products have shown to have inhibitory effects on prostate cancer. We evaluated the effect of a fermented soy beverage (Q-Can®) on men with localized prostate cancer prior to radical prostatectomy.
Methods
We conducted a placebo-controlled, double-blind randomized trial of Q-Can®. Patients were assigned to receive Q-Can® or placebo for 2-5 weeks before radical prostatectomy. The primary endpoint was the change in serum PSA levels from baseline to end-of-study. We also assessed changes in other clinical and pathologic endpoints.
Results
We randomized 19 patients, and 16 were eligible for analysis. Among patients who received Q-Can®, there were no significant changes in PSA levels, prostate cancer characteristics, or serum testosterone. The study was terminated early due to recruitment challenges, and the study power was not achieved.
Conclusions
Short exposure to Q-Can® among patients with localized prostate cancer did not show significant associations with changes in PSA levels, prostate cancer characteristics, or serum testosterone.
Value and Practical Solutions
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates standards, clinical protocols, and research for clinicians. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making patient care and services more manageable in today’s healthcare environment. By using AI, clinics can enhance workflows and improve patient outcomes, reducing paper routines. Learn more about how we can help at aidevmd.com.
